Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07147023 · ClinicalTrials.gov registry record · NA

Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication

A NA study of Cancer and Advanced Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
60
Enrollment target
2
Study locations

NCT07147023: Active NA study of Cancer and Advanced Cancer, sponsored by Dana-Farber Cancer Institute.

NCT07147023 is a NA study of Cancer and Advanced Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 60 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07147023, a NA study of Cancer and Advanced Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

The goal of this study is to test the accuracy of Large Language Model-generated serious illness communication (SIC) summaries, the feasibility of delivering the SIC summaries, and to collect perspectives on the SIC summaries from clinicians and participants with cancer. Large Language Models (LLMs) are artificial intelligence programs that can perform various natural language processing tasks.

Primary Outcome

Primary outcome: We will assess SIC summary accuracy by reviewing the source documentation for each bullet point of the 5 domains of the SIC summary. The RA will read each bullet point, read the source note for the date cited in the summary and indicate with a 1 (supported) or 0 (not supported) whether the documentation supports the summarized point. If a summarized point is scored as 0, the MPIs will independently review the item and assign a 1 or 0 to indicate whether the unsupported summary c

Interventions

  • OTHER LLM SIC Summary Email

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-09-15
Est. Completion 2026-10-31
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the registry record for NCT07147023 still lists

NCT07147023 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which LLM SIC Summary Email is the first listed.

NCT07147023 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07147023 about?

NCT07147023 is a clinical study titled "Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication". The goal of this study is to test the accuracy of Large Language Model-generated serious illness communication (SIC) summaries, the feasibility of delivering the SIC summaries, and to collect perspectives on the SIC summaries from clinicians and participants with cancer. Large Language Models (LLMs)...

What is the current status of trial NCT07147023?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-09-15. Estimated completion is 2026-10-31.

What conditions does trial NCT07147023 study?

This clinical trial studies the following conditions: Cancer, Advanced Cancer, End of Life.

What interventions are being tested in trial NCT07147023?

The interventions under investigation include: LLM SIC Summary Email (OTHER).

Who is sponsoring clinical trial NCT07147023?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07147023 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07147023's enrollment target sits among peer trials

60 393rd of 615 higher than 208 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07147023, the US trial registry maintained by the National Library of Medicine. NCT07147023 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.